Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 13,961 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined treatment Clear all
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

NCT01433172
View directory record Official record
Conditions
Lung Cancer, Adenocarcinoma
Interventions
Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse

NCT02423772
View directory record Official record
Conditions
Chronic Pain, Problematic Opioid Use
Interventions
Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia

NCT00643981
View directory record Official record
Conditions
Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis, Coronary Arteriosclerosis
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

NCT03619837
View directory record Official record
Conditions
Hepatitis C, Transplantation Disease Transmission
Interventions
Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT01780545
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
OGX-427, Docetaxel
Drug
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Regional Anesthesia and Breast Cancer Recurrence

NCT00418457
View directory record Official record
Conditions
Breast Neoplasms
Interventions
General anesthesia and opioids, Regional analgesia and propofol
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
2,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management

NCT04059172
View directory record Official record
Conditions
Pain, Orofacial
Interventions
Ibuprofen 200 mg and acetaminphen 650 mg, Ibuprofen 200 mg, Placebo oral tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

NCT02403895
View directory record Official record
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
Open-label AZD2014, paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00084877
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
triapine, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

NCT04211675
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma
Interventions
Natural Killer Cells, Temozolomide, Irinotecan, Dinutuximab, Sargramostim
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 29 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MPDL3280A, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne

NCT00658112
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl Peroxide
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma

NCT03076281
View directory record Official record
Conditions
Larynx, LIP, Oral Cavity, Pharynx
Interventions
Metformin Hydrochloride, Doxycycline, Metformin +Doxycycline
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

NCT03242772
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
36 Months to 131 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

NCT01012895
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Anaheim, California • Coronado, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

NCT00000895
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate, Nevirapine, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

NCT01218477
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT03922477
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atezolizumab, Hu5F9-G4
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00840177
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, idarubicin, pravastatin sodium
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
185
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 123 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02101775
View directory record Official record
Conditions
Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
8
States / cities
Duarte, California • South Pasadena, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Phase 1 Interventional

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 15, 2026, 5:39 PM EDT